It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
It is very uncertain whether the intervention changes any adverse event (very low certainty).
It is very uncertain whether the intervention changes withdrawal due to adverse event (very low certainty).
It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).
It is very uncertain whether LMWH + standard therapy changes clinical remission compared with standard therapy (very low certainty).
It is very uncertain whether LMWH + standard therapy changes clinical improvement compared with standard therapy (very low certainty).
It is very uncertain whether LMWH + standard therapy changes endoscopic remission compared with standard therapy (very low certainty).
It is very uncertain whether LMWH + standard therapy changes endoscopic improvement compared with standard therapy (very low certainty).
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
Type I Interferons showed no clear difference in remission compared with placebo (moderate certainty).
Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
Methotrexate showed no clear difference in maintenance of remission compared with placebo (low certainty).
It is very uncertain whether methotrexate changes maintenance of remission compared with 5‐ASA (very low certainty).
It is very uncertain whether methotrexate changes maintenance of Remission compared with 6‐MP (very low certainty).
It is very uncertain whether methotrexate + sulfasalazine changes maintenance of Remission compared with sulfasalazine (very low certainty).
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).